D.E. Shaw & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

D.E. Shaw & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-42,000	Closed	-$6.42M	–	5162
2021 Q1	$6.42M	Sell	42,000 -20,000	-32%	-$3.09M	0.01%	1677
2020 Q4	$9.69M	Hold	62,000	–	–	0.01%	1397
2020 Q3	$7.09M	Buy	62,000 +11,300	+22%	+$1.22M	0.01%	1457
2020 Q2	$5.69M	Sell	50,700 -81,200	-62%	-$8.62M	0.01%	1572
2020 Q1	$11.8M	Buy	131,900 +46,300	+54%	+$4.54M	0.02%	900
2019 Q4	$9.26M	Buy	85,600 +54,800	+178%	+$5.86M	0.01%	1249
2019 Q3	$3.02M	Buy	30,800 +20,000	+185%	+$2.25M	﹤0.01%	2053
2019 Q2	$1.42M	Buy	10,800 +900	+9%	+$116K	﹤0.01%	2471
2019 Q1	$1.34M	Sell	9,900 -1,700	-15%	-$211K	﹤0.01%	2426
2018 Q4	$1.13M	Buy	11,600 +1,600	+16%	+$189K	﹤0.01%	2572
2018 Q3	$1.39M	Hold	10,000	–	–	﹤0.01%	2458
2018 Q2	$1.24M	Sell	10,000 -10,000	-50%	-$1.17M	﹤0.01%	2561
2018 Q1	$2.23M	Sell	20,000 -10,000	-33%	-$1.2M	﹤0.01%	1978
2017 Q4	$3.59M	Buy	+30,000	New	+$3.65M	﹤0.01%	1720
2017 Q1	–	Sell	-20,400	Closed	-$2.5M	–	3698
2016 Q4	$2.5M	Sell	20,400 -400	-2%	-$48.9K	﹤0.01%	1829
2016 Q3	$2.55M	Buy	20,800 +10,800	+108%	+$1.39M	﹤0.01%	1738
2016 Q2	$1.17M	Buy	+10,000	New	+$1.42M	﹤0.01%	2315
2016 Q1	–	Sell	-30,200	Closed	-$5.76M	–	3895
2015 Q4	$5.76M	Hold	30,200	–	–	0.01%	1307
2015 Q3	$4.72M	Sell	30,200 -10,000	-25%	-$1.82M	0.01%	1434
2015 Q2	$7.27M	Sell	40,200 -10,000	-20%	-$1.73M	0.01%	1213
2015 Q1	$8.7M	Sell	50,200 -24,400	-33%	-$4.42M	0.01%	1052
2014 Q4	$13.8M	Hold	74,600	–	–	0.02%	902
2014 Q3	$12.4M	Sell	74,600 -11,400	-13%	-$1.87M	0.02%	951
2014 Q2	$13.4M	Sell	86,000 -17,200	-17%	-$2.72M	0.02%	905
2014 Q1	$15.7M	Buy	103,200 +58,600	+131%	+$9.32M	0.02%	782
2013 Q4	$5.93M	Buy	44,600 +30,200	+210%	+$3.62M	0.01%	1539
2013 Q3	$1.67M	Sell	14,400 -16,000	-53%	-$1.76M	﹤0.01%	2582
2013 Q2	$2.8M	Buy	+30,400	New	+$2.93M	0.01%	1807

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

D.E. Shaw & Co's ALXN Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,241,928 shares — an estimated $228M sold.

D.E. Shaw & Co first reported a position in ALXN in Q2 2013 and held it in 30 quarters. The position peaked at $228M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

D.E. Shaw & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
D.E. Shaw & Co sold 1,241,928 Alexion Pharmaceuticals shares in Q3 2021, an estimated $228M.
D.E. Shaw & Co first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 30 quarters.
D.E. Shaw & Co's Alexion Pharmaceuticals position peaked at $228M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.